^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lifastuzumab vedotin (DNIB0600A)

    i
    Other names: DNIB0600A, RG7599, DNIB-0600A, RG-7599, anti-NaPi2b ADC
    Company:
    Roche
    Drug class:
    Microtubule inhibitor, NaPi2b-targeted antibody-drug conjugate
    Related drugs:
    over4years
    Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. (PubMed, Gynecol Oncol)
    LIFA in combination with carboplatin ± bevacizumab demonstrated acceptable safety and encouraging activity in PSOC patients.
    Clinical • P1 data • Journal
    |
    SLC34A2 (Solute carrier family 34 member 2)
    |
    Avastin (bevacizumab) • carboplatin • lifastuzumab vedotin (DNIB0600A)